Ramucirumab, a VEGFR-2 antagonist, based on a phase I/II clinical study (NCT02999295), combined with nivolumab and paclitaxel as second-line treatments for advanced GC, showed a mOS of 13.1 months, ORR of 37.2 %, and a 6-month PFS rate of 46.5 %, significantly benefiting patients with advanced GC [43]. Here, KDR is linked to gastric cancer.